메뉴 건너뛰기
Drugs
Volumn 66, Issue SUPPL. 2, 2006, Pages 25-27
Complete resolution of severe diarrhoea after conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium (myfortic®) in a patient at high immunological risk
Author keywords

[No Author keywords available]
Indexed keywords

CORTICOSTEROID; CYCLOSPORIN; GANCICLOVIR; MYCOPHENOLIC ACID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; THYMOCYTE ANTIBODY;
EID: 33751501957     PISSN: 00126667     EISSN: 00126667     Source Type: Journal    
DOI: 10.2165/00003495-200666991-00010     Document Type: Article
Times cited : (2)
References (7)
  • 1
    • 0033663061 scopus 로고    scopus 로고
    • Effect of mycophenolate mofetil on long-term outcomes in African American renal transplant recipients
    • Meier-Kriesche HU, Ojo AO, Leichtman AB, et al. Effect of mycophenolate mofetil on long-term outcomes in African American renal transplant recipients. J Am Soc Nephrol 2000; 11: 2366-70
    • (2000) J Am Soc Nephrol , vol.11 , pp. 2366-2370
    • Meier-Kriesche, H.U.1    Ojo, A.O.2    Leichtman, A.B.3
  • 2
    • 0034660104 scopus 로고    scopus 로고
    • Mycophenolate mofetil reduces late renal allograft loss independent of acute rejection
    • Ojo AO, Meier-Kriesche HU, Hanson JA, et al. Mycophenolate mofetil reduces late renal allograft loss independent of acute rejection. Transplantation 2000; 69: 2405-9
    • (2000) Transplantation , vol.69 , pp. 2405-2409
    • Ojo, A.O.1    Meier-Kriesche, H.U.2    Hanson, J.A.3
  • 3
    • 12144273473 scopus 로고    scopus 로고
    • Long-term outcomes of gastrointestinal complications in renal transplant patients treated with mycophenolate mofetil
    • Hardinger KL, Brennan DC, Lowell J, Schnitzler MA. Long-term outcomes of gastrointestinal complications in renal transplant patients treated with mycophenolate mofetil. Transplant Int 2004; 17: 609-16
    • (2004) Transplant Int , vol.17 , pp. 609-616
    • Hardinger, K.L.1    Brennan, D.C.2    Lowell, J.3    Schnitzler, M.A.4
  • 4
    • 0037663784 scopus 로고    scopus 로고
    • The impact of mycophenolate mofetil dosing patterns on clinical outcome after renal transplantation
    • Pelletier RP, Akin B, Henry ML, et al. The impact of mycophenolate mofetil dosing patterns on clinical outcome after renal transplantation. Clin Transplant 2003; 17: 200-5
    • (2003) Clin Transplant , vol.17 , pp. 200-205
    • Pelletier, R.P.1    Akin, B.2    Henry, M.L.3
  • 5
    • 1342325540 scopus 로고    scopus 로고
    • Enteric-coated mycophenolate sodium can be safely administered in maintenance renal transplant patients: Results of a 1-year study
    • Budde K, Curtis J, Knoll G, et al. Enteric-coated mycophenolate sodium can be safely administered in maintenance renal transplant patients: results of a 1-year study. Am J Transplant 2004; 4: 237-43
    • (2004) Am J Transplant , vol.4 , pp. 237-243
    • Budde, K.1    Curtis, J.2    Knoll, G.3
  • 6
    • 17844380029 scopus 로고    scopus 로고
    • Mycophenolic acid metabolite profile in renal transplant patients receiving enteric-coated mycophenolate sodium or mycophenolate mofetil
    • Tedesco-Silva H, Bastien M-C, Choi L, et al. Mycophenolic acid metabolite profile in renal transplant patients receiving enteric-coated mycophenolate sodium or mycophenolate mofetil. Transplant Proc 2005; 37: 852-5
    • (2005) Transplant Proc , vol.37 , pp. 852-855
    • Tedesco-Silva, H.1    Bastien, M.-C.2    Choi, L.3
  • 7
    • 0033979599 scopus 로고    scopus 로고
    • Nephrotoxicity of immunosuppressive drugs: Long-term consequences and challenges for the future
    • de Mattos AM, Olyaei AJ, Bennett WM. Nephrotoxicity of immunosuppressive drugs: long-term consequences and challenges for the future. Am J Kidney Dis 2000; 35: 333-46
    • (2000) Am J Kidney Dis , vol.35 , pp. 333-346
    • De Mattos, A.M.1    Olyaei, A.J.2    Bennett, W.M.3

* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.